NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 215 filers reported holding NEVRO CORP in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $229,697 | -10.5% | 6,354 | -1.9% | 0.00% | – |
| Q4 2022 | $256,529 | +16.6% | 6,478 | +37.5% | 0.00% | – |
| Q3 2022 | $220,000 | -19.7% | 4,712 | -24.7% | 0.00% | – |
| Q2 2022 | $274,000 | -15.7% | 6,261 | +39.3% | 0.00% | – |
| Q1 2022 | $325,000 | -5.2% | 4,495 | +6.4% | 0.00% | – |
| Q4 2021 | $343,000 | -40.0% | 4,226 | -14.0% | 0.00% | -100.0% |
| Q3 2021 | $572,000 | -60.9% | 4,913 | -44.3% | 0.00% | 0.0% |
| Q2 2021 | $1,463,000 | +48.5% | 8,822 | +25.0% | 0.00% | 0.0% |
| Q1 2021 | $985,000 | +14.5% | 7,060 | +42.1% | 0.00% | 0.0% |
| Q4 2020 | $860,000 | +72.3% | 4,969 | +38.7% | 0.00% | 0.0% |
| Q3 2020 | $499,000 | +42.2% | 3,582 | +21.9% | 0.00% | 0.0% |
| Q2 2020 | $351,000 | +65.6% | 2,939 | +38.9% | 0.00% | – |
| Q1 2020 | $212,000 | -14.9% | 2,116 | -0.2% | 0.00% | – |
| Q4 2019 | $249,000 | – | 2,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |